UBS Group Cuts Cabot (NYSE:CBT) Price Target to $86.00

Cabot (NYSE:CBT) had its target price decreased by equities research analysts at UBS Group from $92.00 to $86.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group’s price target indicates a potential upside of 11.13% from the company’s current price.

A number of other brokerages have also recently commented on CBT. Wall Street Zen cut Cabot from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research report on Friday, August 21st. Mizuho boosted their price objective on shares of Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. increased their target price on shares of Cabot from $70.00 to $78.00 and gave the company an “underweight” rating in a research note on Friday, August 7th. Finally, Truist Financial set a $100.00 target price on shares of Cabot in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $87.80.

Cabot Price Performance

Shares of NYSE:CBT traded up $0.44 on Monday, reaching $77.39. The company’s stock had a trading volume of 294,301 shares, compared to its average volume of 461,805. The company has a 50-day simple moving average of $82.83 and a 200 day simple moving average of $82.22. Cabot has a 52-week low of $58.33 and a 52-week high of $94.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.97 and a current ratio of 1.47. The company has a market cap of $3.99 billion, a P/E ratio of 21.80, a PEG ratio of 9.06 and a beta of 0.83.

Cabot (NYSE:CBT) last announced its quarterly earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.01. The firm had revenue of $982.00 million during the quarter, compared to the consensus estimate of $943.16 million. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. As a group, equities research analysts anticipate that Cabot will post 6.35 EPS for the current fiscal year.

Insider Activity

In related news, CEO Sean Keohane sold 134,895 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $85.00, for a total value of $11,466,075.00. Following the transaction, the chief executive officer owned 404,134 shares of the company’s stock, valued at $34,351,390. This trade represents a 25.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 229,597 shares of company stock worth $19,646,746 over the last ninety days. 3.08% of the stock is currently owned by insiders.

Institutional Trading of Cabot

Several institutional investors and hedge funds have recently modified their holdings of the stock. QRG Capital Management Inc. grew its holdings in Cabot by 6.0% during the 2nd quarter. QRG Capital Management Inc. now owns 3,433 shares of the specialty chemicals company’s stock worth $312,000 after acquiring an additional 194 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Cabot by 1.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 183,849 shares of the specialty chemicals company’s stock valued at $16,697,000 after purchasing an additional 3,068 shares in the last quarter. State Street Corp lifted its position in shares of Cabot by 6.8% in the 2nd quarter. State Street Corp now owns 2,165,434 shares of the specialty chemicals company’s stock worth $196,665,000 after purchasing an additional 138,098 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Cabot during the second quarter valued at approximately $148,000. Finally, Paragon Capital Management Ltd purchased a new position in Cabot during the second quarter valued at approximately $251,000. Institutional investors own 93.18% of the company’s stock.

About Cabot

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company develops and manufactures materials used by industrial and consumer-product manufacturers worldwide.

Cabot’s products include reinforcing carbon blacks used in tires, automotive components, and other rubber products; specialty carbon blacks used in coatings, plastics, inks, and batteries; and fumed silica used in adhesives, sealants, coatings, and personal-care applications.